Skip to main content

Table 4 Hemodynamic and gas exchange response to inhaled nitric oxide (INO), dobutamine, and INO plus dobutamine in cystic fibrosis (8 patients)

From: Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension

  Baseline INO Dobutamine INO+Dobutamine
Cardiac index (l/min/m2) 3.6 ± 0.6 3.6 ± 0.5 5.1± 0.6 4.7± 0.5**
Heart rate (beats/min) 90 ± 26 90 ± 25 102 ± 22 104 ± 18
SVI (ml/m2) 43 ± 12 43 ± 10 52 ± 10 47 ± 7
CVP (mmHg) 1.4 ± 1.9 1.6 ± 2.1 1.9 ± 2.4 1.4 ± 2
MPAP (mmHg) 24 ± 4 22 ± 3 26 ± 5 24 ± 3
PAOP (mmHg) 5.7 ± 2.7 6.5 ± 3.5 6.2 ± 3.3 5.6 ± 2.6
MPAP-PAOP (mmHg) 18 ± 2 16 ± 2* 20 ± 2 18 ± 3
PVRI (dyne/s/cm5/m2) 591 ± 148 548 ± 140 448 ± 96* 460 ± 98*
MAP (mmHg) 83 ± 15 83 ± 11 87 ± 13 89 ± 13
SVRI (dyne/s/cm5/m2) 1826 ± 261 1825 ± 230 1371 ± 193 1495 ± 197**
Qs/Qt (%) 20 ± 7 17 ± 4 30 ± 6* 22 ± 5
PaO2/FiO2 (mmHg) 276 ± 56 350 ± 48* 260 ± 56 319 ± 65
PaCO2 (mmHg) 54 ± 11 55 ± 11 54 ± 12 53 ± 12
  1. *P < 0.05; **P < 0.01. CVP, cardiovenous pressure; INO, inhaled nitric oxide; MAP, mean systemic arterial pressure; MPAP, mean pulmonary arterial pressure; PAOP, pulmonary artery occluded pressure; PVRI, pulmonary vascular resistance index; SVI, systemic vascular index; SVRI, systemic vascular resistance index.